DK0941095T3 - Forbedrede farmaceutiske sammensætninger - Google Patents

Forbedrede farmaceutiske sammensætninger

Info

Publication number
DK0941095T3
DK0941095T3 DK97948461T DK97948461T DK0941095T3 DK 0941095 T3 DK0941095 T3 DK 0941095T3 DK 97948461 T DK97948461 T DK 97948461T DK 97948461 T DK97948461 T DK 97948461T DK 0941095 T3 DK0941095 T3 DK 0941095T3
Authority
DK
Denmark
Prior art keywords
improved
pharmaceutical compositions
improved pharmaceutical
resuspendability
suspensions
Prior art date
Application number
DK97948461T
Other languages
Danish (da)
English (en)
Inventor
Todd P Foster
David L Kiefer
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0941095(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0941095T3 publication Critical patent/DK0941095T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97948461T 1996-12-09 1997-12-03 Forbedrede farmaceutiske sammensætninger DK0941095T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions
PCT/US1997/021401 WO1998025621A1 (fr) 1996-12-09 1997-12-03 Compositions pharmaceutiques ameliorees

Publications (1)

Publication Number Publication Date
DK0941095T3 true DK0941095T3 (da) 2004-08-02

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97948461T DK0941095T3 (da) 1996-12-09 1997-12-03 Forbedrede farmaceutiske sammensætninger

Country Status (22)

Country Link
US (1) US5736151A (fr)
EP (1) EP0941095B1 (fr)
JP (1) JP2001505910A (fr)
KR (1) KR100544248B1 (fr)
CN (1) CN100413506C (fr)
AT (1) ATE264681T1 (fr)
AU (1) AU746666B2 (fr)
BR (1) BR9714967B1 (fr)
CA (1) CA2269682C (fr)
CZ (1) CZ297632B6 (fr)
DE (1) DE69728783T2 (fr)
DK (1) DK0941095T3 (fr)
ES (1) ES2218705T3 (fr)
FI (1) FI991302A0 (fr)
HK (1) HK1023292A1 (fr)
HU (1) HUP0000564A3 (fr)
NO (1) NO325475B1 (fr)
NZ (1) NZ336183A (fr)
PL (1) PL190662B1 (fr)
PT (1) PT941095E (fr)
SK (1) SK72399A3 (fr)
WO (1) WO1998025621A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
JP4738713B2 (ja) * 2000-09-12 2011-08-03 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 修飾された担体を含む医薬組成物
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
AU2002328168B2 (en) * 2002-08-07 2008-08-21 Merial Ltd. Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
MXPA05009978A (es) * 2003-03-20 2005-11-04 Pharmacia Corp Formulacion dispersable de un agente antiinflamatorio.
KR100807414B1 (ko) * 2003-07-31 2008-02-25 파마시아 앤드 업존 캄파니 엘엘씨 유선염 및 귀 장애의 치료를 위한 분산성 약학 조성물
WO2006008640A1 (fr) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Suspension non aqueuse contenant un medicament a gout desagreable
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
EP2123255B1 (fr) * 2007-02-16 2013-05-15 ASKA Pharmaceutical Co., Ltd. Composition pharmaceutique contenant une suspension à base d'huile en fines particules
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
AU2009316708B2 (en) 2008-11-19 2014-07-17 Boehringer Ingelheim Animal Health USA Inc. Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
PL2874624T3 (pl) 2012-07-17 2020-07-27 Bayer New Zealand Limited 3 Argus Place Hillcrest, Auckland 0627 / NZ Wstrzykiwalne formulacje antybiotykowe i sposoby ich zastosowania
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10420776B2 (en) * 2016-10-13 2019-09-24 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
EP3606527A1 (fr) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Agoniste de ppar-gamma pour le traitement de la paralysie supranucléaire progressive
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
NL260648A (fr) * 1961-01-31
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
US4937330A (en) * 1985-08-12 1990-06-26 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
DE3887691T2 (de) * 1987-11-10 1994-06-09 Upjohn Co Cephalosporin-antibiotika.
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
JPH04506216A (ja) * 1989-06-13 1992-10-29 アボツト・ラボラトリーズ 薬物送達用の油を主成分とした非水性液体懸濁液
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje

Also Published As

Publication number Publication date
AU746666B2 (en) 2002-05-02
ATE264681T1 (de) 2004-05-15
CZ202599A3 (cs) 1999-09-15
FI991302A (fi) 1999-06-08
KR100544248B1 (ko) 2006-01-23
EP0941095A1 (fr) 1999-09-15
DE69728783D1 (de) 2004-05-27
NO325475B1 (no) 2008-05-13
SK72399A3 (en) 2000-05-16
DE69728783T2 (de) 2005-03-31
CN100413506C (zh) 2008-08-27
WO1998025621A1 (fr) 1998-06-18
KR20000069360A (ko) 2000-11-25
AU5452998A (en) 1998-07-03
US5736151A (en) 1998-04-07
CZ297632B6 (cs) 2007-02-14
PT941095E (pt) 2004-08-31
EP0941095B1 (fr) 2004-04-21
BR9714967A (pt) 2001-10-30
PL190662B1 (pl) 2005-12-30
FI991302A0 (fi) 1999-06-08
CA2269682A1 (fr) 1998-06-18
ES2218705T3 (es) 2004-11-16
CN1238690A (zh) 1999-12-15
JP2001505910A (ja) 2001-05-08
NO992780D0 (no) 1999-06-08
NO992780L (no) 1999-06-08
BR9714967B1 (pt) 2010-06-29
NZ336183A (en) 2000-12-22
HUP0000564A3 (en) 2001-01-29
HUP0000564A2 (hu) 2000-10-28
CA2269682C (fr) 2009-04-14
HK1023292A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
DK0941095T3 (da) Forbedrede farmaceutiske sammensætninger
IL149163A0 (en) Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them
NZ505163A (en) Sustained release medicinal compositions comprising an ionic compound with an opposite charge to the ionic active substance
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
PT1263730E (pt) Derivados amina para o tratamento de apoptose
UA37181C2 (uk) ГІДРОХЛОРИД 7-<font face="Symbol">b</font>-[(Z)-2-(2-АМІНО-4-ТІАЗОЛІЛ)-3-ГІДРОКСИІМІНОАЦЕТА- МІДО]-3-(1,2,3-ТРИАЗОЛ-4-ІЛ)ТІОМЕТИЛТІО-3-ЦЕФЕМ-4-КАРБОНОВОЇ КИСЛОТИ АБО ЙОГО ГІДРАТИ, ЩО МАЮТЬ АНТИБАКТЕРІАЛЬНУ ДІЮ, ФАРМАЦЕВТИЧНА АНТИБАКТЕРІАЛЬНА КОМПОЗИЦІЯ, СПОСІБ ПРИГНІЧЕННЯ РОЗВИТКУ БАКТЕРІЙ, СПОСІБ ЛІКУВАННЯ БАКТЕРІАЛЬНИХ ІНФЕКЦІЙ
FR2743562B1 (fr) Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
GT199900208A (es) Antibiòticos cetòlidos carbamato y carbazato.
FR2754258B1 (fr) Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
DE69626981D1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
ATE196899T1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
IT1277663B1 (it) Sospensioni acquose stabili di mesalazina per uso topico
DE69627344D1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
DE69330601D1 (de) Serotoninergische ergolin derivate
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
EA200000522A1 (ru) 5-htагонисты
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их
FR2707496B1 (fr) Compositions pharmaceutiques antiradicalaires et/ou antilipoperoxydantes et/ou hépatotropes.
NO20010624D0 (no) N-substituerte azacykloheptanderivater, fremstilling og anvendelse derav